To include your compound in the COVID-19 Resource Center, submit it here.

Chronic neuroprotection

How inhibiting DLK could be neuroprotective in both ALS and AD

Two studies by Genentech have shown DLK inhibition is neuroprotective in two chronic neurodegenerative diseases and suggest the target may play a broad role in driving neurodegeneration, regardless of the underlying cause.

MAP kinase kinase kinase 12 (DLK; MAP3K12) is primarily expressed in neuronal cells, where it plays roles in stress response and neuronal injury. Previous studies showed inhibition of the c-jun

Read the full 610 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE